Sanofi

Stocks

SAN

FR0000120578

Market Closed - Euronext Paris 11:55:00 2026-08-20 EDT			5-day change	1st Jan Change
77.79 ^EUR	-0.98%		+3.14%	-5.96%

08-20	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
08-20	Cancer vaccines finally garner the spotlight

Transcript : Sanofi - Special Call

Published on 12/16/2025 at 01:20 pm EST - Modified on 12/16/2025 at 09:50 pm EST

S&P Capital IQ

Presenter Speech
Thomas Larsen (Executives)

Good afternoon and good morning, depending on where you are, and welcome to the Sanofi's first year-end late-stage pipeline review. I'm Thomas Kudsk Larsen

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Sanofi

08-20	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
08-20	Cancer vaccines finally garner the spotlight
08-19	Sanofi : Deutsche Bank reiterates its Buy rating	ZD
08-19	Sanofi : UBS reiterates its Neutral rating	ZD
08-18	European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading	MT
08-17	Paris stocks less cautious than their European peers
08-14	AlphaValue still cautious about Sanofi
08-13	Sanofi: Q2 beat gets sidelined by burning pipeline issues
08-11	InduPro, Inc. announced that it has received $77 million in funding from a group of investors	CI
08-11	Global drugmakers invest billions to boost US presence	RE
08-10	Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says	MT
08-10	Innate Pharma surges after a deal that secures its cash runway for another year
08-10	Bernstein Expects Novo Nordisk to Continue Facing US GLP-1 Share Loss, Margin Pressure	MT
08-07	Sanofi : Gets a Buy rating from Jefferies	ZD
08-06	Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand	RE